

Nightmare Disorder

DSM-5-TR 307.47 | ICD-10-CM F51.5

Repeated well-remembered dysphoric dreams that wake the sleeper fully alert, producing distress, sleep avoidance, and daytime impairment.

ADULT PREVALENCE

~2-6% weekly nightmares

TYPICAL ONSET

Ages 3-6; peaks in teens

IN PTSD

~50-90% report nightmares

COURSE

Often chronic if untreated

CLINICAL PICTURE

- Extended dysphoric dreams involving threat to survival, security, or physical integrity, recalled in vivid narrative detail on awakening.
- The awakening is rapid and fully oriented, which is the cardinal feature distinguishing nightmares from the confusion of sleep terrors.
- Episodes cluster in the second half of the night when REM sleep predominates, typically in the hours after 3 a.m.
- Autonomic arousal is present but modest compared with the tachycardia, sweating, and screaming of NREM arousal disorders.
- Sleep avoidance emerges as patients delay bedtime to escape dreaming, producing secondary insomnia and cumulative sleep deprivation.
- Daytime sequelae include intrusive dream imagery, mood disturbance, fatigue, and mounting anxiety as nightfall approaches.

DIAGNOSTIC CRITERIA AT A GLANCE

- Repeated extended and well-remembered dysphoric dreams, usually involving threats to survival, security, or physical integrity.
- On awakening from the dysphoric dream the person becomes rapidly oriented and alert with clear recall of the dream content.
- Clinically significant distress or impairment is required, so nightmares without daytime consequence do not meet the threshold.
- Specify acute at one month or less, subacute at one to six months, and persistent at six months or longer, plus a frequency-based severity rating.
- Not attributable to a substance or medical condition, and not better explained by another mental disorder such as PTSD.

NEUROBIOLOGY & PHYSIOLOGY

- Nightmares arise in REM sleep with heightened limbic activation in the **amygdala** and anterior cingulate alongside reduced prefrontal regulation.
- The failed REM fear-extinction model holds that REM normally decouples emotional charge from memory, and nightmares represent that failure.
- Noradrenergic tone is elevated during REM in trauma-related nightmares, which is the rationale for alpha-1 blockade with **prazosin**.
- Heritability estimates run roughly 35% to 45%, with twin data supporting a shared diathesis with anxiety and dissociative traits.
- Beta blockers, SSRIs, varenicline, dopamine agonists, and abrupt withdrawal of REM suppressants all provoke nightmares pharmacologically.
- Frequent nightmares independently predict suicidal ideation and attempts even after controlling for depression and insomnia severity.

PSYCHOLOGICAL MECHANISMS

- Nightmares function as a conditioned cue, turning the bed into a threat context so that avoidance reinforces both insomnia and fear.
- Continuity theory holds that dream content tracks waking concerns, so nightmare themes map onto current stressors and trauma memory.
- Rescripting works by changing the dream schema through rehearsal rather than by exposing the patient to the trauma content itself.
- Nightmare-related distress predicts impairment better than raw nightmare frequency, making distress the more useful treatment target.
- Childhood nightmares are usually developmental and self-limiting, but persistence past adolescence signals elevated psychopathology risk.

DIFFERENTIAL & COMORBIDITY

- Sleep terrors occur in early-night NREM sleep with confusion, amnesia, and an intense autonomic surge rather than clear dream recall.
- REM sleep behavior disorder features dream enactment with vigorous movement, which nightmare disorder lacks because REM atonia stays intact.
- Nocturnal panic attacks arise from NREM sleep without dream content, and nocturnal seizures are brief, stereotyped, and highly repetitive.
- PTSD, depression, borderline personality disorder, and substance withdrawal are the dominant comorbidities to screen for at intake.
- Nightmares are an independent suicide risk factor, so ask about them directly rather than assuming depression accounts for the risk.

Treatment EVIDENCE-BASED MANAGEMENT

PHARMACOLOGIC

- Prazosin** titrated from 1 mg upward to 10-15 mg at bedtime is the best-studied agent for trauma-related nightmares despite one large negative trial.
- Monitor first-dose orthostatic hypotension and syncope with prazosin, dosing at bedtime and titrating slowly, especially in older adults.
- Treating the underlying disorder helps, since **sertraline**, **paroxetine**, or **venlafaxine** reduce nightmares as PTSD or depression remits.
- Withdraw offending agents where possible: beta blockers, varenicline, dopamine agonists, and abruptly discontinued REM suppressants.
- Trazodone**, **topiramate**, and low-dose atypical antipsychotics carry weak evidence, and benzodiazepines do not treat nightmares.

PSYCHOTHERAPY

- Imagery rehearsal therapy** across 4 to 6 sessions is first-line: the patient rewrites the nightmare into a new ending and rehearses it daily.
- Exposure, relaxation, and rescripting therapy** adds sleep scheduling and exposure to rescripting and achieves comparable outcomes.
- CBT-I** addresses the sleep avoidance and conditioned arousal that nightmares generate and is frequently delivered concurrently.
- Lucid dreaming therapy and systematic desensitization have supportive but distinctly weaker evidence than rescripting approaches.
- Trauma-focused protocols including **cognitive processing therapy** and **prolonged exposure** reduce nightmares as PTSD symptoms improve.

ADJUNCT & SUPPORTIVE

- Track frequency, intensity, and distress in a nightly log rather than relying on retrospective recall at widely spaced visits.
- Address the sleep deprivation caused by avoidance directly, since curtailed sleep produces REM rebound and more nightmares.
- Screen for and treat comorbid sleep apnea, as positive airway pressure alone reduces PTSD-related nightmare frequency in some patients.
- Limit alcohol and cannabis, both of which suppress REM sleep and generate rebound nightmares during withdrawal.
- A structured wind-down, reduced evening exposure to violent media, and a safe well-lit environment lower nocturnal threat priming.

- ☆ **CLINICAL PEARLS**
- Imagery rehearsal beats medication and works without reliving the trauma itself.
 - Nightmares independently raise suicide risk; ask about them and about safety.
 - Confused, amnestic, early-night episodes are sleep terrors, not nightmares.

References

American Psychiatric Association. (2022). *Diagnostic and statistical manual of mental disorders* (5th ed., text rev.).

<https://doi.org/10.1176/appi.books.9780890425787>

Boland, R., Verduin, M. L., & Ruiz, P. (2021). *Kaplan & Sadock's synopsis of psychiatry* (12th ed.). Wolters Kluwer.

Krakow, B., Hollifield, M., Johnston, L., Koss, M., Schrader, R., Warner, T. D., Tandberg, D., Lauriello, J., McBride, L., Cutchen, L., Cheng, D., Emmons, S., Germain, A., Melendrez, D., Sandoval, D., & Prince, H. (2001). Imagery rehearsal therapy for chronic nightmares in sexual assault survivors with posttraumatic stress disorder: A randomized controlled trial. *JAMA*, 286(5), 537-545.

<https://doi.org/10.1001/jama.286.5.537>

Morgenthaler, T. I., Auerbach, S., Casey, K. R., Kristo, D., Maganti, R., Ramar, K., Zak, R., & Kartje, R. (2018). Position paper for the treatment of nightmare disorder in adults: An American Academy of Sleep Medicine position paper. *Journal of Clinical Sleep Medicine*, 14(6), 1041-1055. <https://doi.org/10.5664/jcsm.7178>

Raskind, M. A., Peskind, E. R., Chow, B., Harris, C., Davis-Karim, A., Holmes, H. A., Hart, K. L., McFall, M., Mellman, T. A., Reist, C., Romesser, J., Rosenheck, R., Shih, M.-C., Stein, M. B., Swift, R., Gleason, T., Lu, Y., & Huang, G. D. (2018). Trial of prazosin for post-traumatic stress disorder in military veterans. *The New England Journal of Medicine*, 378(6), 507-517. <https://doi.org/10.1056/NEJMoa1507598>

Sateia, M. J. (2014). International classification of sleep disorders-third edition: Highlights and modifications. *Chest*, 146(5), 1387-1394. <https://doi.org/10.1378/chest.14-0970>

U.S. Department of Veterans Affairs & U.S. Department of Defense. (2023). *VA/DoD clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder*. <https://www.healthquality.va.gov/guidelines/MH/ptsd/>

NOTE

References are formatted in APA 7th edition style with hanging indents. Diagnostic terminology, criteria structure, and coding follow the *Diagnostic and Statistical Manual of Mental Disorders* (5th ed., text rev.; APA, 2022); criteria are paraphrased for instructional use and are not reproduced verbatim. Verify all citations against the original sources before use in academic work, and confirm medication dosing against current prescribing information.